Background: Patients with anti–melanoma differentiation–associated gene 5 (MDA5) antibody–positive dermatomyositis (DM) frequently develop rapidly progressive interstitial lung disease and may also ...
Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart’s Phase III results are promising, but ...